Who we are and what we do
Etubics
Corporation is a Seattle based biopharmaceutical company with a proprietary "next
generation" Adenovirus
Vector Vaccines Platform (AVVP) technology that enables the rapid development
of safe and novel therapeutic and preventative vaccines.
Etubics established laboratories in July 2006 at the Seattle
Life Sciences Center in Seattle, Wash. In July 2009, the Company moved into a
new facility located at 410 W. Harrison Street, Suite 100, Seattle, Wash.
98119. The current facility supports all
research and development, pilot manufacturing, regulatory, administrative and
operational requirements for the next three years. The Company currently has
nine employees but has the facilities to support up to 25 employees.
Our Mission,
To develop "next generation" vector vaccines and immunotherapies to
immunize and alleviate large worldwide populations from difficult to
treat diseases such as certain cancers, influenza viruses, HIV and
malaria.